NTRK1 and lung carcinoma: (2) Both lapatinib resistant cell lines contained a damaging mutation in ALK, which is a receptor tyrosine kinase that has been previously associated with multiple cancer types [8,20,29] and is an activating mutation in many types of lung cancer [8].